Trial Profile
An Open Label Phase 3 Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Eptinezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Registrational
- Acronyms PREVAIL
- Sponsors Alder Biopharmaceuticals
- 19 Jun 2023 According to Lundbeck Inc media release, data from this study will be presented at the 65th Annual Scientific Meeting of the American Headache Society (AHS)
- 28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology
- 08 Jul 2019 According to an Alder Biopharmaceuticals media release, data from the study will be presented at the American Headache Society's (AHS) 61st Annual Scientific Meeting 2019.